Metastatic Breast Cancer | Tumor

CURE’s metastatic breast cancer page features the latest cancer news and updates on metastatic breast cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in metastatic breast cancer.

Vepdegestrant May Reduce Disease Progression in Breast Cancer Subset

March 11th 2025, 4:14pm

Article

Vepdegestrant improved progression-free survival in patients with estrogen receptor 1 mutations in advanced ER-positive, HER2-negative breast cancer.

Camizestrant Combo Improves Progression Time in HR+/HER2– Breast Cancer

March 1st 2025, 3:00pm

Article

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer.

Metronomic Capecitabine and an AI Improve Survival in HR+/HER2– Metastatic Breast Cancer

February 27th 2025, 2:00pm

Article

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative metastatic breast cancer.

What Patients With Breast Cancer Need to Know About Itovebi and Blood Sugar

February 26th 2025, 4:24pm

Video

An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.

Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer

February 19th 2025, 8:00pm

Article

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.

Are We at Risk of Losing Our Breast Cancer Community?

February 14th 2025, 6:00pm

Article

I found community after my metastatic breast cancer diagnosis, but recent discord in cancer support groups makes me fear we're losing these vital connections.

An Expert Explains the Enhertu Approval in HER2-Low and -Ultralow Breast Cancer

February 12th 2025, 2:00pm

Video

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Breaking Down Cancer Therapies Approved by the FDA in January 2025

February 3rd 2025, 4:00pm

Article

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.

Strutting Into Year 11 With Metastatic Breast Cancer

January 30th 2025, 6:00pm

Article

After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with confidence and self-advocacy.

Itovebi-Based Treatment Has OS Benefit in PIK3CA+ HR+/HER2– Breast Cancer

January 30th 2025, 2:00pm

Article

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.